Ontology type: schema:ScholarlyArticle Open Access: True
2021-12-18
AUTHORSMasataka Honda, Hideki Horiuchi, Tomoko Torii, Akihiro Nakajima, Takeshi Iijima, Hiroshi Murano, Hisashi Yamanaka, Shuichi Ito
ABSTRACTBackgroundOur previous research showed that uric acid lowering therapy (ULT) for gout and hyperuricemia is being prescribed for pediatric patients even though these drugs have not been approved for use in children. However, the actual clinical situation has not been clearly elucidated. In this paper, we provide an in-depth look at the details of actual clinical practice.MethodsThis retrospective cross-sectional study accessed health insurance data for 696,277 children from April 2016 through March 2017 to identify pediatric patients with gout or asymptomatic hyperuricemia, calculate the proportion of patients prescribed ULTs, and analyze population characteristics. Adherence and mean dose for febuxostat and allopurinol, the most commonly prescribed drugs, were also analyzed.ResultsAmong children with gout or asymptomatic hyperuricemia, we found that 35.1% (97/276) were prescribed ULT. This proportion increased with age, especially among males. By comorbidity, ULT was prescribed to 47.9% (46/96) of patients with kidney disease, 41.3% (26/63) for cardiovascular disease, 40.0% (6/15) for Down syndrome, and 27.1% (32/118) for metabolic syndrome. In patients with kidney disease, febuxostat was prescribed more than twice as frequently as allopurinol (28 vs. 12). Median values for the medication possession ratio (MPR) of febuxostat and allopurinol were 70.1 and 76.7%, respectively, and prescriptions were continued for a relatively long period for both drugs. Both drugs were prescribed at about half the adult dose for patients 6–11 years old and about the same as the adult dose for patients 12–18 years old.ConclusionsThis study showed that the continuous management of serum uric acid is being explored using off-label use of ULT in pediatric patients with gout or asymptomatic hyperuricemia in Japan. Drug selection is based on patient characteristics such as sex, age, and comorbidities, and pediatric dosage is based on usage experience in adults. To develop appropriate pediatric ULT, clinical trials are needed on the efficacy and safety of ULT in the pediatric population.Trial registrationUMIN000036029. More... »
PAGES581
http://scigraph.springernature.com/pub.10.1186/s12887-021-03051-x
DOIhttp://dx.doi.org/10.1186/s12887-021-03051-x
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1144004427
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/34922491
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adolescent",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Child",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Cross-Sectional Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Gout",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Gout Suppressants",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Hyperuricemia",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Insurance, Health",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Japan",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Retrospective Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Uric Acid",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Clinical Research Support Center, Tokyo Metropolitan Children\u2019s Medical Center, Musashidai 2-8-29, 183-8561, Fuchu-shi, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.417084.e",
"name": [
"Clinical Research Support Center, Tokyo Metropolitan Children\u2019s Medical Center, Musashidai 2-8-29, 183-8561, Fuchu-shi, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Honda",
"givenName": "Masataka",
"id": "sg:person.01300112777.86",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300112777.86"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Medical Science Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, 100-8585, Chiyoda-ku, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.419889.5",
"name": [
"Medical Science Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, 100-8585, Chiyoda-ku, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Horiuchi",
"givenName": "Hideki",
"id": "sg:person.012440353373.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012440353373.14"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Medical Science Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, 100-8585, Chiyoda-ku, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.419889.5",
"name": [
"Medical Science Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, 100-8585, Chiyoda-ku, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Torii",
"givenName": "Tomoko",
"id": "sg:person.015243315571.90",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015243315571.90"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Pharmaceutical Development Administration Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, 100-8585, Chiyoda-ku, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.419889.5",
"name": [
"Pharmaceutical Development Administration Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, 100-8585, Chiyoda-ku, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Nakajima",
"givenName": "Akihiro",
"id": "sg:person.015427442431.82",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015427442431.82"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Pharmaceutical Development Coordination Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, 100-8585, Chiyoda-ku, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.419889.5",
"name": [
"Pharmaceutical Development Coordination Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, 100-8585, Chiyoda-ku, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Iijima",
"givenName": "Takeshi",
"id": "sg:person.010133205371.47",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010133205371.47"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Pharmaceutical Development Coordination Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, 100-8585, Chiyoda-ku, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.419889.5",
"name": [
"Pharmaceutical Development Coordination Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, 100-8585, Chiyoda-ku, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Murano",
"givenName": "Hiroshi",
"id": "sg:person.011526146371.06",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011526146371.06"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Institute of Rheumatology, Tokyo Women\u2019s Medical University, Kawada-cho 8-1, 162-8666, Shinjuku-ku, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.410818.4",
"name": [
"Rheumatology, Sanno Medical Center, Akasaka 8-5-35, 107-0052, Minato-ku, Tokyo, Japan",
"Department of Rheumatology, International University of Health and Welfare, Kozunomori 4-3, 286-8686, Narita-shi, Chiba, Japan",
"Institute of Rheumatology, Tokyo Women\u2019s Medical University, Kawada-cho 8-1, 162-8666, Shinjuku-ku, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Yamanaka",
"givenName": "Hisashi",
"id": "sg:person.01332171373.37",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332171373.37"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Fukuura 3-9, Kanazawa-ku, 236-0004, Yokohama-shi, Kanagawa, Japan",
"id": "http://www.grid.ac/institutes/grid.268441.d",
"name": [
"Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Fukuura 3-9, Kanazawa-ku, 236-0004, Yokohama-shi, Kanagawa, Japan"
],
"type": "Organization"
},
"familyName": "Ito",
"givenName": "Shuichi",
"id": "sg:person.012302533312.63",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012302533312.63"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/ejhg.2012.304",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1040366640",
"https://doi.org/10.1038/ejhg.2012.304"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00467-008-1006-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1011907281",
"https://doi.org/10.1007/s00467-008-1006-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf00858973",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1039108738",
"https://doi.org/10.1007/bf00858973"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00256-013-1771-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1037199960",
"https://doi.org/10.1007/s00256-013-1771-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/1546-0096-12-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1046690430",
"https://doi.org/10.1186/1546-0096-12-1"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00467-010-1599-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003290619",
"https://doi.org/10.1007/s00467-010-1599-6"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf01957519",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1006687747",
"https://doi.org/10.1007/bf01957519"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00296-011-2106-5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1040511723",
"https://doi.org/10.1007/s00296-011-2106-5"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00467-018-3943-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1101555613",
"https://doi.org/10.1007/s00467-018-3943-1"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/s12887-020-02379-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1131721512",
"https://doi.org/10.1186/s12887-020-02379-0"
],
"type": "CreativeWork"
}
],
"datePublished": "2021-12-18",
"datePublishedReg": "2021-12-18",
"description": "BackgroundOur previous research showed that uric acid lowering therapy (ULT) for gout and hyperuricemia is being prescribed for pediatric patients even though these drugs have not been approved for use in children. However, the actual clinical situation has not been clearly elucidated. In this paper, we provide an in-depth look at the details of actual clinical practice.MethodsThis retrospective cross-sectional study accessed health insurance data for 696,277 children from April 2016 through March 2017 to identify pediatric patients with gout or asymptomatic hyperuricemia, calculate the proportion of patients prescribed ULTs, and analyze population characteristics. Adherence and mean dose for febuxostat and allopurinol, the most commonly prescribed drugs, were also analyzed.ResultsAmong children with gout or asymptomatic hyperuricemia, we found that 35.1% (97/276) were prescribed ULT. This proportion increased with age, especially among males. By comorbidity, ULT was prescribed to 47.9% (46/96) of patients with kidney disease, 41.3% (26/63) for cardiovascular disease, 40.0% (6/15) for Down syndrome, and 27.1% (32/118) for metabolic syndrome. In patients with kidney disease, febuxostat was prescribed more than twice as frequently as allopurinol (28 vs. 12). Median values for the medication possession ratio (MPR) of febuxostat and allopurinol were 70.1 and 76.7%, respectively, and prescriptions were continued for a relatively long period for both drugs. Both drugs were prescribed at about half the adult dose for patients 6\u201311\u2009years old and about the same as the adult dose for patients 12\u201318\u2009years old.ConclusionsThis study showed that the continuous management of serum uric acid is being explored using off-label use of ULT in pediatric patients with gout or asymptomatic hyperuricemia in Japan. Drug selection is based on patient characteristics such as sex, age, and comorbidities, and pediatric dosage is based on usage experience in adults. To develop appropriate pediatric ULT, clinical trials are needed on the efficacy and safety of ULT in the pediatric population.Trial registrationUMIN000036029.",
"genre": "article",
"id": "sg:pub.10.1186/s12887-021-03051-x",
"inLanguage": "en",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1024635",
"issn": [
"1471-2431"
],
"name": "BMC Pediatrics",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "21"
}
],
"keywords": [
"medication possession ratio",
"asymptomatic hyperuricemia",
"cross-sectional study",
"pediatric patients",
"adult dose",
"pediatric population",
"kidney disease",
"MethodsThis retrospective cross-sectional study",
"Japanese health insurance database",
"retrospective cross-sectional study",
"proportion of patients",
"urate-lowering therapy",
"Health Insurance Database",
"serum uric acid",
"uric acid",
"actual clinical practice",
"health insurance data",
"ResultsAmong children",
"actual clinical situation",
"possession ratio",
"patients 6",
"patients 12",
"patient characteristics",
"metabolic syndrome",
"pediatric dosages",
"insurance database",
"label use",
"clinical trials",
"cardiovascular disease",
"patients",
"clinical practice",
"hyperuricemia",
"clinical situations",
"gout",
"drug selection",
"Down syndrome",
"ConclusionsThis study",
"allopurinol",
"febuxostat",
"disease",
"drugs",
"dose",
"comorbidities",
"syndrome",
"therapy",
"median value",
"children",
"insurance data",
"age",
"population characteristics",
"population",
"years",
"ULT",
"proportion",
"trials",
"study",
"adherence",
"efficacy",
"adults",
"prescription",
"sex",
"males",
"long period",
"dosage",
"safety",
"acid",
"use",
"continuous management",
"management",
"period",
"database",
"previous research",
"experience",
"characteristics",
"practice",
"data",
"ratio",
"Japan",
"values",
"research",
"selection",
"depth look",
"situation",
"detail",
"look",
"usage experience",
"paper"
],
"name": "Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database",
"pagination": "581",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1144004427"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s12887-021-03051-x"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"34922491"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s12887-021-03051-x",
"https://app.dimensions.ai/details/publication/pub.1144004427"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-10T10:30",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_881.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1186/s12887-021-03051-x"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12887-021-03051-x'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12887-021-03051-x'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12887-021-03051-x'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12887-021-03051-x'
This table displays all metadata directly associated to this object as RDF triples.
304 TRIPLES
22 PREDICATES
136 URIs
118 LITERALS
20 BLANK NODES